Climate & Earth Systems | Jan 3, 2026 | 8 min read | By Bryan White

Spirochaetes Bacteria and the Ixodes Tick: Lyme Disease in a Warming World

Biology * Climate Change * Public Health

An Ancient Pathogen in the Anthropocene

Lyme borreliosis, caused by the spirochete Borrelia burgdorferi sensu lato and transmitted by Ixodes ticks, is the most prevalent vector-borne public health challenge in the Northern Hemisphere.[2][3] First identified clinically in the mid-1970s in Lyme, Connecticut, B. burgdorferi actually survived Pleistocene ice sheets in North American refugia for hundreds of millennia.[1][10] Its late-20th-century emergence stemmed not from a de novo mutation, but from reforestation and suburban fragmentation that brought humans into the spirochete's enzootic cycle.[1][2]

The CDC estimates that 476,000 Americans are diagnosed and treated for Lyme disease annually, with reported cases jumping 69% to over 62,000 after a 2022 laboratory-based surveillance revision.[3][28] Concurrently, anthropogenic climate change is accelerating vector expansion into Canada and Appalachia, while the 2025 National Academies (NASEM) report on Lyme Infection-Associated Chronic Illnesses (Lyme IACI) has reshaped clinical research.[5][9] Integrating genomics, ecology, immunology, and climatology illuminates how this pathogen thrives in the Anthropocene.

Evolutionary Genomics and the Enzootic Dilution Debate

B. burgdorferi possesses an unusual multipartite genome among bacteria: a conserved linear chromosome paired with up to 21 dynamic plasmids encoding outer surface proteins (like ospC on cp26) under diversifying selection against host antibody responses.[8][11][12] Contrasting generalist B. burgdorferi with louse-borne Borrelia recurrentis illustrates divergent spirochetal evolution:[13]

| Feature | | Borrelia burgdorferi (Lyme Agent) | | Borrelia recurrentis (Relapsing Fever) |

| Vector & Age | | Hard Ticks (Ixodes spp.); ancient (pre-LGM)[10] | | Body Louse; recent (~2,000-6,000 yrs)[13] |

| Genome & Niche | | Conserved chromosome + 21 plasmids; generalist[11] | | Reductive evolution & gene loss; human-louse specialist[13] |

Disease epidemiology tracks the two-year life cycle of Ixodes scapularis.[15] Uninfected larvae acquire B. burgdorferi during their first blood meal before molting into nymphs.[4] The white-footed mouse (Peromyscus leucopus) is the primary hyper-competent reservoir, infecting 40-90% of feeding larvae without clinical illness, whereas white-tailed deer amplify adult tick populations without transmitting the bacterium.[16][17][18] While the "Dilution Effect" links high biodiversity to reduced infection prevalence, 2024-2025 studies note

context-dependent amplification, though forest fragmentation consistently favors hyper-competent mice.[19][20][21]

Molecular Pathogenesis and Climate-Driven Range Expansion

In unfed tick midguts, spirochetes express OspA bound to TROSPA receptors.[22] Blood engorgement downregulates OspA and induces OspC, which binds host complement C4b while CspZ recruits Factor H -- disarming complement lysis during bloodstream dissemination.[22][23][24] Meanwhile, warmer winters and increased degree-days are expanding tick habitats:[5][25][26]

| Region | | 2025 Status | | 2050 Projection & Climatic Driver |

| Canada (ON/QC) | | Rapid emergence[5][6] | | 250-500 km northward shift to 50 deg N via warmer winters & degree-days.[5][26] |

| Northeast & Midwest US | | Hyper-endemic / Invasion[3] | | Woodland consolidation & earlier spring nymphal phenology.[27][39] |

| Appalachia & South | | Altitudinal spread[7][28] | | Up-slope mountain spread; potential southern heat/drought contraction.[27][28] |

Lyme IACI Consensus and the 2025-2026 Therapeutic Pipeline

Although doxycycline cures most early cases, 10-20% of patients experience persistent fatigue, pain, and cognitive deficits.[9][32] The 2025 NASEM consensus report formalized Lyme IACI (formerly PTLDS), linking chronic symptoms to neuroinflammation (IL-6/CXCL8), retained peptidoglycan "ghost" debris, and neuropathic injury.[9][29][30][31] Three targeted modalities define the 2025-2026 therapeutic pipeline:[31][33][36]

| Intervention | | Target & Mechanism | | 2025-2026 Clinical Status |

| VLA15 Vaccine (Pfizer/Valneva) | | 6-serotype recombinant OspA; host antibodies neutralize bacteria inside the feeding tick gut.[14][36] | | Positive Phase 3 VALOR topline efficacy reported in March 2026 (73.2% 28 days post-dose 4; 74.8% 1 day post-dose 4); EMA Marketing Authorization Application validated in August 2026, with U.S. FDA Biologics License Application submission anticipated in early 2027 following regulatory package alignment.[36][37][38] |

| Hygromycin A / FP530 (Flightpath) | | Spirochete-selective inhibition; hygromycin A (FP-100) targets ribosomes, while next-generation FP530 (forazemin) inhibits peptide deformylase while sparing the gut microbiome.[33][34] | | FP-100 Phase 1 testing paused in May 2026 due to limited human oral bioavailability; program pivoted to oral candidate FP530 (forazemin).[33] |

| FGFR Inhibitors (Tulane) | | Blocks host Fibroblast Growth Factor Receptors to suppress remnant-driven neuroinflammation.[29][31] | | Preclinical primate tissue validation.[29][35] |

Breaking the Enzootic and Chronic Cycle

As climate warming expands Ixodes ranges northward and upward, the convergence of the 2025 NASEM Lyme IACI framework, transmission-blocking VLA15 vaccination, microbiome-sparing spirochete inhibitors (building on hygromycin A toward FP530),

and neuroprotective FGFR inhibitors equips medicine to interrupt vector transmission and resolve chronic post-infectious sequelae.[5][9][33][36]

Updates... (Nov 22, 2026): Verified all 39 references against live CrossRef, OpenAlex, ClinicalTrials.gov, and publisher metadata; updated publication dates for CDC Blacklegged Tick Surveillance (May 14, 2026), Contagion Live (May 21, 2024), Flightpath Biosciences (May 2026), and ClinicalTrials.gov NCT05477524 (2022; updated Jun 4, 2026).

References & Primary Sources

* [1] Hoen, A. G., Margos, G., Bent, S. J., Diuk-Wasser, M. A., & Barbour, A. (2009). Phylogeography of Borrelia burgdorferi in the eastern United States reflects multiple independent Lyme disease emergence events. PNAS. -- https://doi.org/10.1073/pnas.0903810106

* [2] EUCLID Global Health (2025). Lyme Disease in the United States: Emerging Trends and Public Health Challenges. -- https://globalhealth.euclid.int/lyme-disease-in-the-united-states-emerging-trends-and-public-health-challenges/

* [3] CDC (2025). Lyme Disease Surveillance and Data. -- https://www.cdc.gov/lyme/data-research/facts-stats/index.html

* [4] Contagion Live (2025). What is Driving the Global Expansion of Lyme Disease? -- https://www.contagionlive.com/view/changes-in-latitude-changes-altitude-what-is-driving-the-global-expansion-of-lyme-disease-

* [5] Simon, J. A., Marrotte, R. R., Desrosiers, N., Fiset, J., Gaitan, J., et al. (2014). Climate change and habitat fragmentation drive the occurrence of Borrelia burgdorferi, the agent of Lyme disease, at the northeastern limit of its distribution. Evolutionary Applications. -- https://doi.org/10.1111/eva.12165

* [6] CityNews Toronto (2025). Climate change is driving a rise in tick-borne diseases. Here's what to know. -- https://toronto.citynews.ca/2025/06/28/climate-change-is-driving-a-rise-in-tick-borne-diseases-heres-what-to-know/

* [7] UNCG Research (2025). New study finds ticks carrying Lyme disease moving into western NC. -- https://research.uncg.edu/news/wasserberg-study-finds-ticks-carrying-lyme-disease-moving-into-western-nc/

* [8] Foor, S. D., Brangulis, K., Shakya, A. K., Rana, V. S., Bista, S., et al. (2023). A unique borrelial protein facilitates microbial immune evasion. mBio. -- https://doi.org/10.1128/mbio.02135-23

* [9] National Academies of Sciences, Engineering, and Medicine (2025). Charting a Path Toward New Treatments for Lyme Infection-Associated Chronic Illnesses. The National Academies Press. -- https://doi.org/10.17226/28578

* [10] Walter, K. S., Carpi, G., Caccone, A., & Diuk-Wasser, M. A. (2017). Genomic insights into the ancient spread of Lyme disease across North America. Nature Ecology & Evolution. -- https://doi.org/10.1038/s41559-017-0282-8

* [11] Akther, S., Mongodin, E. F., Morgan, R. D., Di, L., Yang, X., et al. (2024). Natural selection and recombination at host-interacting lipoprotein loci drive genome diversification of Lyme disease and related bacteria. mBio. --

https://doi.org/10.1128/mbio.01749-24

* [12] Qiu, W.-G., & Martin, C. L. (2014). Evolutionary genomics of Borrelia burgdorferi sensu lato: Findings, hypotheses, and the rise of hybrids. Infection, Genetics and Evolution. -- https://doi.org/10.1016/j.meegid.2014.03.025

* [13] Swali, P., Booth, T., Tan, C. C. S., McCabe, J., Anastasiadou, K., et al. (2025). Ancient Borrelia genomes document the evolutionary history of louse-borne relapsing fever. Science. -- https://doi.org/10.1126/science.adr2147

* [14] Grimm, D., Tilly, K., Byram, R., Stewart, P. E., Krum, J. G., et al. (2004). Outer-surface protein C of the Lyme disease spirochete: A protein induced in ticks for infection of mammals. PNAS. -- https://doi.org/10.1073/pnas.0306845101

* [15] CDC (May 14, 2026). Blacklegged Tick Surveillance. -- https://www.cdc.gov/ticks/data-research/facts-stats/blacklegged-tick-surveillance.html

* [16] Cary Institute of Ecosystem Studies (2025). Lyme Disease Research. -- https://www.caryinstitute.org/science/research-projects/lyme-disease-research

* [17] Rogovskyy, A. S., Pliasas, V. C., Buhrer, R., Lewy, K., Wiener, D. J., et al. (2024). Do white-footed mice, the main reservoir of the Lyme disease pathogen in the United States, clinically respond to the borrelial tenancy? Infection and Immunity. -- https://doi.org/10.1128/iai.00382-24

* [18] Brunner, J. L., LoGiudice, K., & Ostfeld, R. S. (2008). Estimating Reservoir Competence of Borrelia burgdorferi Hosts: Prevalence and Infectivity, Sensitivity, and Specificity. Journal of Medical Entomology. -- https://doi.org/10.1093/jmedent/45.1.139

* [19] LoGiudice, K., Ostfeld, R. S., Schmidt, K. A., & Keesing, F. (2003). The ecology of infectious disease: Effects of host diversity and community composition on Lyme disease risk. PNAS. -- https://doi.org/10.1073/pnas.0233733100

* [20] Cary Institute of Ecosystem Studies (2025). Biodiversity, Community Ecology, and the Dilution Effect. -- https://www.caryinstitute.org/science/research-projects/biodiversity-community-ecology-and-dilution-effect

* [21] Chen, S., & McFarlane, S. E. (2025). Reappraisal of the Dilution and Amplification Effect Framework: A Case Study in Lyme Disease. Ecology and Evolution, 15(8), e71969. -- https://doi.org/10.1002/ece3.71969

* [22] Srivastava, S. Y., & de Silva, A. M. (2008). Reciprocal Expression of ospA and ospC in Single Cells of Borrelia burgdorferi. Journal of Bacteriology (via PMC). -- https://pmc.ncbi.nlm.nih.gov/articles/PMC2394987/

* [23] Kumaran, D., Eswaramoorthy, S., Luft, B. J., Koide, S., Dunn, J. J., et al. (2001). Crystal structure of outer surface protein C (OspC) from the Lyme disease spirochete, Borrelia burgdorferi. The EMBO Journal. -- https://doi.org/10.1093/emboj/20.5.971

* [24] Marcinkiewicz, A. L., Brangulis, K., Dupuis, A. P., Hart, T. M., Zamba-Campero, M., et al. (2023). Structural evolution of an immune evasion determinant shapes pathogen host tropism. PNAS. -- https://doi.org/10.1073/pnas.2301549120

* [25] Gray, J. S., Dautel, H., Estrada-Pe a, A., Kahl, O., & Lindgren, E. (2009). Effects of Climate Change on Ticks and Tick-Borne Diseases in Europe. Interdisciplinary Perspectives on Infectious Diseases. -- https://doi.org/10.1155/2009/593232

* [26] Westcott, J. R., Bowden, J. J., Savage, J., & Doody, K. M. (2025). Rapid Northward Expansion of the Blacklegged Tick, Ixodes scapularis, in Response to Climate Change. Global Change Biology. -- https://doi.org/10.1111/gcb.70591

* [27] Musa, S. S., & Gumel, A. B. (2026). Could global warming cause a range expansion or shift of Lyme disease in the U.S. state of Maryland? A mathematical modelling approach. Royal Society Open Science, 13(3), 251672. -- https://doi.org/10.1098/rsos.251672

* [28] Garshong, R. A., Adams, D. R., Seagle, S. W., Wasserberg, G., & Reiskind, M. H. (2025). Expanding range of Ixodes scapularis Say (Acari: Ixodidae) and Borrelia burgdorferi infection in North Carolina counties, 2018-2023. PLOS One. -- https://doi.org/10.1371/journal.pone.0329511

* [29] Parthasarathy, G. (2024). Fibroblast growth factor receptor inhibitors mitigate the neuropathogenicity of Borrelia burgdorferi or its remnants ex vivo. Frontiers in Immunology. -- https://doi.org/10.3389/fimmu.2024.1327416

* [30] Northwestern University Feinberg School of Medicine (2025). Post-Treatment Lyme Disease Syndrome May Be Driven by Remnants of Infection. -- https://news.feinberg.northwestern.edu/2025/05/12/post-treatment-lyme-disease-syndrome-may-be-driven-by-remnants-of-infection/

* [31] Tulane University (Summer 2024). New Treatment for Lyme Disease. Tulanian Magazine. -- https://tulanian.tulane.edu/summer-2024/new-treatment-lyme-disease

* [32] UIC Drug Information Group (Jul 2025). What are the most up to date guideline recommendations for the treatment of Lyme disease? -- https://dig.pharmacy.uic.edu/faqs/2025-2/july-2025-faqs/what-are-the-most-up-to-date-guideline-recommendations-for-the-treatment

* [33] Flightpath Biosciences (May 2026). Flightpath Biosciences' Commitment and Direction in Lyme Disease Treatment. -- https://flightpath.bio/flightpath-biosciences-commitment-and-direction-in-lyme-disease-treatment/

* [34] Leimer, N., Wu, X., Imai, Y., Morrissette, M., Pitt, N., et al. (Oct 1, 2021). A selective antibiotic for Lyme disease. Cell. -- https://doi.org/10.1016/j.cell.2021.09.011

* [35] Tulane National Biomedical Research Center (Apr 25, 2024). Study finds potential new treatment path for lasting Lyme disease symptoms. -- https://tnbrc.tulane.edu/news/1652726/Study%20finds%20potential%20new%20treatment%20path%20for%20lasting%20Lyme%20

* [36] Valneva SE (Aug 14, 2026). Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency. -- https://valneva.com/press-release/pfizer-and-valnevas-lyme-disease-vaccine-candidate-marketing-authorization-application-validated

* [37] Valneva SE (Nov 25, 2025). Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate. -- https://valneva.com/wp-content/uploads/2025/11/2025_11_26_VLA15_221_Phase-2_Results-1.pdf

* [38] ClinicalTrials.gov (2022; updated Jun 4, 2026). Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency of a 6-Valent OspA-Based Lyme Disease Vaccine (VALOR, NCT05477524). -- https://clinicaltrials.gov/study/NCT05477524

* [39] CDC / Contagion Live (May 21, 2024). Tick, Tick: Spring Signals the Spread of Lyme Disease in the US. -- https://www.contagionlive.com/view/tick-tick-spring-signals-the-spread-of-lyme-disease-in-the-us